Küleon, LLC

News & Media


PRESS RELEASE | OCTOBER 5, 2023

The Latest Scientific Breakthrough from Küleon Bioscience

The first known “trifunctional” 5-HT2C receptor agonist that is also a full antagonist of the 5-HT2A and 5-HT2B receptors, creating …

More News

Press Release | April 13, 2023:

Küleon Receives Another Favorable PCT Search Report and Written Opinion from WIPO.

Within Küleon’s third patent publication the company discloses a wide array of conformationally-constrained ligands that exhibit unique selectivity for serotonin receptor subtypes.

Press Release | February 23, 2023:

Küleon Receives Favorable PCT Search Report and Written Opinion from WIPO.

Within this patent publication Küleon discloses novel analogs having alkoxy, alkylthio and alkylseleno residues, rendering many of these compounds completely inactive at the 5-HT2B receptor.

Press Release | February 16, 2023:

Küleon’s first Patent Application is Published.

Kuleon’s first patent application, disclosing its proprietary molecular scaffolds and thousands of novel compounds, published by World Intellectual Property Office.